Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $21.8 million.

  • GeneDx Holdings' Net Cash Flow rose 110176.02% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 22948.72%. This contributed to the annual value of -$14.5 million for FY2024, which is 6156.24% up from last year.
  • Per GeneDx Holdings' latest filing, its Net Cash Flow stood at $21.8 million for Q3 2025, which was up 110176.02% from -$25.6 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Net Cash Flow high stood at $424.8 million for Q3 2021, and its period low was -$93.3 million during Q3 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$25.6 million (2025), whereas its average is -$1.2 million.
  • Over the last 5 years, GeneDx Holdings' Net Cash Flow had its largest YoY gain of 3716796.72% in 2021, and its largest YoY loss of 564563.38% in 2021.
  • GeneDx Holdings' Net Cash Flow (Quarter) stood at -$60.7 million in 2021, then fell by 11.07% to -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then soared by 120.67% to $27.3 million in 2024, then decreased by 20.03% to $21.8 million in 2025.
  • Its Net Cash Flow was $21.8 million in Q3 2025, compared to -$25.6 million in Q2 2025 and $14.5 million in Q1 2025.